Saniona publishes its interim report for the second quarter of 2024
| Three Months Ended June 30, 2024 (2023) | Six Months Ended June 30, 2024 (2023) |
| Revenue was SEK 8.0 M (3.9 M) | Revenue was SEK 14.1 M (6.0 M) |
| Operating profit/loss was SEK -16.0 M (-21.8 M) | Operating profit/loss was SEK -29.7 M (-42.9 M) |
| Net profit/loss was SEK -19.7 M (-21.2 M) | Net profit/loss was SEK -29.0 M (-43.0 M) |
| Cash and cash equivalent SEK 54.4 M (69.4) | Cash and cash equivalent SEK 54.4 M (69.4) |
| Basic earnings/loss per share was SEK -0.18 (-0.34) | Basic earnings/loss per share was SEK -0.26 (-0.69) |
| Diluted earnings/loss per share were SEK -0.18 (-0.34) | Diluted earnings/loss per share were SEK -0.26 (-0.69) |
Business highlights in Q2 2024
- On May 7, Saniona reported progress on pipeline and other activities.
- John Haurum was at the Annual General meeting May 29, 2024, elected as a new ordinary board member.
- On June 17, Saniona comments on article addressing the potential mechanism of action behind tesofensine’s unique weight loss effect.
Comments from the CEO
“Our partner, Medix, has submitted an updated application with additional information and documentation for approval of tesofensine in Mexico. The regulatory agency has had no further comments or questions. We remain optimistic about an approval of tesofensine this year for treatment of obesity. We have discussions with potential partners around several assets which may lead to new collaborations this year. Our objective is to make at least one new collaboration on one of our preclinical or clinical assets in 2024 to secure funding for continued development of our company and assets. The two pipeline programs, SAN711 and SAN2355, are progressing in accordance with our plans, which means that we are on track to deliver top-line results for SAN711 by year-end and finalize a GLP tox batch for SAN2355 during the third quarter.”